Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$8.37 -3.7%	$8.11	$6.10 ▼ $28.67	$579.66M	1.46	390,266 shs	125,676 shs
DNTH Dianthus Therapeutics	$18.31 -5.1%	$19.12	$13.37 ▼ $32.27	$588.85M	1.36	280,200 shs	272,904 shs
KYTX Kyverna Therapeutics	$3.22 -6.9%	$2.36	$1.78 ▼ $11.40	$139.17M	2.52	397,663 shs	288,515 shs
MNMD Mind Medicine (MindMed)	$7.17 -1.8%	$6.60	$4.70 ▼ $10.44	$541.72M	2.52	1.36 million shs	985,843 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-2.11%	+3.08%	-13.62%	-65.79%
DNTH Dianthus Therapeutics	0.00%	-2.86%	-2.35%	-14.16%	-27.23%
KYTX Kyverna Therapeutics	0.00%	-5.01%	+47.71%	+28.80%	-76.56%
MNMD Mind Medicine (MindMed)	0.00%	-7.96%	+9.47%	+12.91%	-8.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.3459 of 5 stars	4.4	1.0	2.0	4.2	0.6
DNTH Dianthus Therapeutics	1.3745 of 5 stars	3.6	0.0	2.7	0.8	0.0
KYTX Kyverna Therapeutics	2.4776 of 5 stars	3.6	3.0	3.0	1.7	0.0
MNMD Mind Medicine (MindMed)	1.9202 of 5 stars	3.6	0.0	3.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	198.69% Upside
DNTH Dianthus Therapeutics	3.13	Buy	$53.00	189.46% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	474.53% Upside
MNMD Mind Medicine (MindMed)	3.27	Buy	$25.50	255.65% Upside

Current Analyst Ratings Breakdown

Latest KYTX, BCYC, MNMD, and DNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/13/2025	DNTH Dianthus Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $50.00
5/13/2025	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00
5/2/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$26.00 ➝ $22.00
5/2/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
5/1/2025	BCYC Bicycle Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $15.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$25.72M	22.54	N/A	N/A	$12.35 per share	0.68
DNTH Dianthus Therapeutics	$6.52M	90.26	N/A	N/A	$11.40 per share	1.61
KYTX Kyverna Therapeutics	$7.03M	19.80	N/A	N/A	N/A	∞
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$1.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$180.66M	-$3.14	N/A	N/A	N/A	-450.64%	-27.35%	-20.81%	8/5/2025 (Estimated)
DNTH Dianthus Therapeutics	-$43.56M	-$2.88	N/A	N/A	N/A	-1,250.32%	-21.68%	-20.88%	8/6/2025 (Estimated)
KYTX Kyverna Therapeutics	-$60.37M	-$3.38	N/A	N/A	N/A	N/A	-51.12%	-37.91%	8/11/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$95.73M	-$1.29	N/A	N/A	N/A	N/A	-47.56%	-35.55%	8/12/2025 (Estimated)

Latest KYTX, BCYC, MNMD, and DNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/12/2025	Q1 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.82	+$0.04	-$0.82	$0.81 million	$1.16 million
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million
3/27/2025	Q4 2024	KYTX Kyverna Therapeutics	-$0.87	-$0.88	-$0.01	-$0.88	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	17.13	17.13
DNTH Dianthus Therapeutics	N/A	18.30	18.30
KYTX Kyverna Therapeutics	N/A	10.50	10.50
MNMD Mind Medicine (MindMed)	0.09	9.00	9.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
DNTH Dianthus Therapeutics	47.53%
KYTX Kyverna Therapeutics	18.08%
MNMD Mind Medicine (MindMed)	27.91%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
DNTH Dianthus Therapeutics	8.15%
KYTX Kyverna Therapeutics	22.00%
MNMD Mind Medicine (MindMed)	2.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	63.18 million	Optionable
DNTH Dianthus Therapeutics	80	32.16 million	24.70 million	Optionable
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
MNMD Mind Medicine (MindMed)	40	75.55 million	71.68 million	Optionable

KYTX, BCYC, MNMD, and DNTH Headlines

Recent News About These Companies

Cantor Fitzgerald Comments on MNMD FY2026 Earnings

June 12 at 2:49 AM | americanbankingnews.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives $25.50 Average Price Target from Analysts

June 12 at 1:29 AM | americanbankingnews.com

Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Down 4.8% - Here's Why

June 11, 2025 | marketbeat.com

Equities Analysts Offer Predictions for MNMD FY2026 Earnings

June 10, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Recommendation of "Buy" by Brokerages

June 9, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Sold by Two Sigma Investments LP

June 5, 2025 | marketbeat.com

Millennium Management LLC Increases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

June 5, 2025 | marketbeat.com

Why Mind Medicine Gave Investors a Powerful Buzz in May

June 4, 2025 | msn.com

Bank of America Corp DE Reduces Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

June 4, 2025 | marketbeat.com

Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade

June 2, 2025 | zacks.com

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025 | finance.yahoo.com

HC Wainwright Has Pessimistic Outlook of MNMD Q3 Earnings

May 27, 2025 | marketbeat.com

What is HC Wainwright's Estimate for MNMD Q1 Earnings?

May 25, 2025 | marketbeat.com

Cantor Fitzgerald Has Negative View of MNMD FY2025 Earnings

May 25, 2025 | marketbeat.com

Northern Trust Corp Has $4.77 Million Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

May 24, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Shares Acquired by AWM Investment Company Inc.

May 23, 2025 | marketbeat.com

Tang Capital Management LLC Acquires New Shares in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

May 20, 2025 | marketbeat.com

MindMed Announces New Employee Inducement Grants

May 19, 2025 | businesswire.com

Cantor Fitzgerald Upgrades Mind Medicine (MindMed) (NASDAQ:MNMD) to "Strong-Buy"

May 17, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Rating of "Buy" by Analysts

May 17, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts MNMD FY2025 Earnings

May 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX, BCYC, MNMD, and DNTH Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$8.37 -0.32 (-3.68%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$8.41 +0.04 (+0.53%)

As of 06/13/2025 06:47 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Dianthus Therapeutics NASDAQ:DNTH

$18.31 -0.98 (-5.08%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$18.30 -0.01 (-0.08%)

As of 06/13/2025 04:36 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Kyverna Therapeutics NASDAQ:KYTX

$3.22 -0.24 (-6.94%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.34 +0.12 (+3.57%)

As of 06/13/2025 07:41 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Mind Medicine (MindMed) NASDAQ:MNMD

$7.17 -0.13 (-1.78%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$7.10 -0.07 (-0.98%)

As of 06/13/2025 07:59 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time